18 results
8-K
EX-10.2
ARAV
Aravive Inc
3 Jun 22
Aravive Appoints Rudy Howard as Chief Financial Officer
4:06pm
liabilities, losses, damages, costs, and other expenses (including attorneys’ and expert witnesses’ costs and fees) arising from or relating to any
8-K
EX-99.2
ARAV
Aravive Inc
19 Nov 20
Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian Cancer
7:10am
than those for AXL- or GAS6- patients (51% vs. 75%; P=0.028; 53% vs. 72%; P=0.040) Linger et al. 2012. Expert Opin Ther Targets. 2010 October ; 14(10
8-K
EX-10.4
ARAV
Aravive Inc
9 Jan 20
Aravive Announces Management Changes
4:59pm
and all liabilities, losses, damages, costs, and other expenses (including attorneys’ and expert witnesses’ costs and fees) arising from or relating to any
424B5
rnzp4dd5y8xwmp
27 Nov 19
Prospectus supplement for primary offering
4:07pm
424B5
7ms2prlsjuzl
26 Nov 19
Prospectus supplement for primary offering
5:18pm
S-4
EX-10.1
tvy9px6t4 k2j
3 Aug 18
Registration of securities issued in business combination transactions
5:26pm
S-4
EX-10.8
f125dq4ezci8zcgn
3 Aug 18
Registration of securities issued in business combination transactions
5:26pm
S-4
s3urm6we1focsxtcrku
3 Aug 18
Registration of securities issued in business combination transactions
5:26pm
S-4
EX-10.6
3vvjmf7a hhj
3 Aug 18
Registration of securities issued in business combination transactions
5:26pm
424B4
0bee2fhfs9
22 Jan 15
Prospectus supplement with pricing info
12:00am
424B4
hl3w41 x4
21 Mar 14
Prospectus supplement with pricing info
12:00am
DRS
lvi9s005vfh3wnjtg9la
10 Jan 14
Draft registration statement
12:00am
- Prev
- 1
- Next